EAM Investors’s Organogenesis Holdings ORGO Stock Holding History

EAM Investors’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-249,606	Closed	-$4.55M	–	390
2021 Q1	$4.55M	Buy	+249,606	New	+$3.38M	0.68%	14

Other funds holding ORGO

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMIMC

Northwestern Mutual Investment Management Company Milwaukee, Wisconsin $6.6B AUM 19.75% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM Investors's ORGO Position: Q2 2021 in Review

EAM Investors sold out of Organogenesis Holdings (ORGO) in Q2 2021, closing a stake of 249,606 shares — an estimated $4.55M sold.

EAM Investors first reported a position in ORGO in Q1 2021 and held it in 1 quarter. The position peaked at $4.55M in Q1 2021. 142 funds tracked by Wall St. Rank hold ORGO as of Q2 2021.

EAM Investors reported no remaining Organogenesis Holdings position as of Q2 2021 after selling out during the quarter.
EAM Investors sold 249,606 Organogenesis Holdings shares in Q2 2021, an estimated $4.55M.
EAM Investors first reported a position in Organogenesis Holdings in Q1 2021 and held it in 1 quarter.
EAM Investors's Organogenesis Holdings position peaked at $4.55M in Q1 2021.
142 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2021.

Based on EAM Investors's 13F filing for Q2 2021, filed 13 Aug 2021.